Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports that its B7-H3-targeted antibody-drug conjugate GSK'227, now called risvutatug rezetecan, has received Orphan Drug Designation from the US FDA for treating small-cell lung cancer (SCLC). This decision is based on early phase I ARTEMIS-001 data showing durable responses in patients with extensive-stage SCLC, a form of the disease with high relapse rates, few treatment options and a five-year survival rate of about 3%.
This is the fifth major regulatory designation for risvutatug rezetecan, following EMA Orphan Drug Designation in pulmonary neuroendocrine carcinoma, EMA PRIME status in relapsed extensive-stage SCLC, and two US FDA Breakthrough Therapy Designations in relapsed or refractory ES-SCLC and osteosarcoma. GSK has begun a global phase III trial in relapsed extensive-stage SCLC, positioning this investigational therapy as a key part of its oncology pipeline.
GSK plc reported a share transaction by a senior manager. Sally Jackson, SVP, Global Communications & CEO Office, sold 6,000 ordinary shares of GSK on the London Stock Exchange. The shares were sold at a price of £18.2870 per share on 2025-12-05. This disclosure is a routine notification of dealings by a person discharging managerial responsibilities in GSK’s securities.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 229,000 ordinary shares on 8 December 2025 as part of its existing share buyback programme. The shares, each with a nominal value of 31¼ pence, were bought at prices between 1,803.00p and 1,822.00p per share, with a volume‑weighted average price of 1,814.42p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,474,733 ordinary shares. After this latest transaction, it holds 237,939,577 shares in treasury and has 4,077,499,560 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by the treasury shares is 5.84%, a reference figure for investors monitoring notification thresholds under UK disclosure rules.
GSK plc reports that on 05 December 2025 it repurchased 248,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,798.00p and 1,833.00p per share, with a volume-weighted average price of 1,818.74p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,245,733 ordinary shares. Following this latest purchase, the company holds 237,710,577 shares in treasury and has 4,077,728,560 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.83% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that it repurchased 233,000 of its ordinary shares of 31¼ pence each on 4 December 2025 under its existing share buyback programme, using BNP Paribas SA as broker. The shares were bought at prices between 1,819.00p and 1,852.50p per share, with a volume-weighted average price of 1,832.36p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought 11,997,733 ordinary shares under this programme. After this latest purchase, GSK holds 237,462,577 shares in treasury and has 4,077,971,107 ordinary shares in issue, which is also the total number of voting rights. The company states that, following this transaction, treasury shares represent 5.82% of the voting rights.
GSK plc reports that on 03 December 2025 it repurchased 218,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,830.00p and 1,848.00p, with a volume-weighted average price of 1,839.30p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,764,733 ordinary shares under this programme. After this latest transaction, GSK holds 237,229,577 ordinary shares in treasury and has 4,078,204,107 ordinary shares in issue, giving a total of 4,078,204,107 voting rights. The percentage of voting rights attributable to treasury shares is stated as 5.82 per cent.
GSK plc reports that on 02 December 2025 it repurchased 200,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA as part of its existing share buyback programme. The shares were bought at prices between 1,783.00p and 1,827.00p, with a volume-weighted average price of 1,815.48p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 11,546,733 ordinary shares under this programme. After the latest transaction, the company holds 237,011,577 shares in treasury and has 4,078,422,107 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares represent 5.81 per cent of the voting rights, a figure relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 203,000 ordinary shares on 01 December 2025 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,786.00p and 1,810.00p, with a volume-weighted average price of 1,800.44p.
After this transaction, GSK holds 236,811,577 ordinary shares in treasury and has 4,078,622,107 ordinary shares in issue excluding treasury shares. The total number of voting rights in GSK is 4,078,622,107, and the company states that treasury shares represent 5.81% of the voting rights, which shareholders can use as a reference for regulatory disclosure thresholds.
GSK plc filed a Form 6-K reporting option grants to three senior executives under the Company’s Share Save Plan 2022. James Ford (SVP and Group General Counsel, Legal and Compliance), David Redfern (President, Corporate Development), and Victoria Whyte (SVP & Company Secretary) each received options over 643 Ordinary Shares of 31¼ pence at an option price of £14.19 per share.
The grants were made on 2025-11-28 and relate to GSK’s Ordinary Shares with ISIN GB00BN7SWP63, with the transactions conducted on the London Stock Exchange (XLON). These awards form part of GSK’s regular share-based compensation for senior management and do not change the company’s stated business strategy as a global biopharma company.
GSK plc reports its share capital and voting rights position as at 30 November 2025. The company had 4,315,433,684 issued Ordinary Shares of 31 ¼ pence each, of which 236,608,577 Ordinary Shares were held in treasury. After excluding the treasury shares, the total number of voting rights in GSK is 4,078,825,107. Shareholders can use this voting-rights figure to determine whether they need to notify GSK and the UK regulator of any changes in their shareholdings under the applicable transparency rules.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
